Clinical Study to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transplantation in Patients With High-risk Acute Myeloid Leukemia

This study is testing whether infusions of specially prepared immune cells called gamma-delta T cells — from the donor — can help prevent leukemia from coming back after a bone marrow transplant (allogeneic stem cell transplant) in people with high-risk acute myeloid leukemia (AML), a fast-growing blood cancer. **You may be eligible if...** - You are between 18 and 65 years old - You have acute myeloid leukemia (AML) with high-risk factors for relapse - You are planning to undergo or have recently had an allogeneic stem cell transplant (a transplant using cells from a donor) **You may NOT be eligible if...** - You do not have high-risk features for relapse - You have significant organ dysfunction - You are not a candidate for transplant Talk to your doctor to see if this trial is right for you.